Related Experiment Video

Updated: May 9, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

[Juvenile idiopathic arthritis]

Abdellah El Maghraoui1

  • 1Hôpital militaire d'instruction Mohammed V, service de rhumatologie, Rabat, Maroc.

Presse Medicale (Paris, France : 1983)
|July 27, 2013
PubMed

Insights

Juvenile idiopathic arthritis (JIA) is a complex autoimmune condition in children. Advances in treatment, including anticytokine agents, have significantly improved outcomes for young patients.

Area of Science:

  • Rheumatology
  • Immunology
  • Pediatrics

Context:

  • Juvenile idiopathic arthritis (JIA) is a heterogeneous group of autoimmune arthritides of unknown etiology, affecting individuals before the age of 16.
  • The precise causes of JIA are not fully understood, but likely involve a complex interplay of genetic predisposition and environmental triggers.
  • Despite its complexity, significant advancements in disease management have led to improved prognoses for affected children.

Purpose:

  • To provide an overview of juvenile idiopathic arthritis, encompassing its diverse clinical presentations and underlying etiological factors.
  • To highlight recent therapeutic advancements, particularly the role of novel agents in managing refractory cases.
  • To underscore the importance of ongoing research into immune response mechanisms for future treatment development.

Summary:

  • JIA presents with varied clinical signs and potential genetic links, making diagnosis and treatment challenging.
  • The introduction of anticytokine agents offers a crucial new treatment avenue for patients unresponsive to traditional therapies.
  • Continued research into the immune system and inflammation is key to unlocking further therapeutic innovations for JIA.

Impact:

  • Improved treatment strategies have substantially enhanced the long-term outlook for children with JIA.
  • Novel biologic therapies, such as anticytokine agents, represent a significant breakthrough for treatment-resistant JIA.
  • Enhanced understanding of disease pathogenesis promises the development of more targeted and effective future therapies.

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...